Immunohistochemical analysis of renal oxidative damage in senior and geriatric cats with chronic kidney disease

Kurahara, Natsume; Yutsudo, Ayami; Furusawa, Yu; Yamato, Osamu; Miyoshi, Noriaki; Hifumi, Tatsuro; Yabuki, Akira

doi:10.1016/j.jcpa.2023.09.001

Cited by 2 publications

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite several reports, there is still little insight into the role of oxidative stress in the pathophysiology of feline CKD due to inconsistency in the results of published studies [ 18 – 27 ]. It has been suggested that antioxidant defence mechanisms are induced in feline CKD [ 19 , 20 ] and that oxidative stress may be highest in the early stages of CKD in cats as indicated by the increased levels of plasma and urine F2-isprostanes [ 22 , 23 ], a well-known and reliable biomarker of lipid peroxidation and thus oxidative stress [ 28 – 30 ].…”

Section: Introductionmentioning

confidence: 99%

Supplementation of vitamin E as an addition to a commercial renal diet does not prolong survival of cats with chronic kidney disease

Krofič Žel,

Tavčar Kalcher,

Vovk

et al. 2024

BMC Vet Res

View full text Add to dashboard Cite

Background The aim of this double-blind, placebo-controlled study was to investigate the effect of vitamin E supplementation as an addition to a commercial renal diet on survival time of cats with different stages of chronic kidney disease (CKD). In addition, we were interested whether vitamin E supplementation affects selected oxidative stress and clinical parameters. Thirty-four cats with CKD and 38 healthy cats were included in the study. Cats with CKD were classified according to the IRIS Guidelines; seven in IRIS stage 1, 15 in IRIS stage 2, five in IRIS stage 3 and seven in IRIS stage 4. Cats with CKD were treated according to IRIS Guidelines. Cats with CKD were randomly assigned to receive vitamin E (100 IU/cat/day) or placebo (mineral oil) for 24 weeks in addition to standard therapy. Plasma malondialdehyde (MDA) and protein carbonyl (PC) concentrations, DNA damage of peripheral lymphocytes and plasma vitamin E concentrations were measured at baseline and four, eight, 16 and 24 weeks thereafter. Routine laboratory analyses and assessment of clinical signs were performed at each visit. Results Vitamin E supplementation had no effect on the survival time and did not reduce the severity of clinical signs. Before vitamin E supplementation, no significant differences in vitamin E, MDA and PC concentrations were found between healthy and CKD cats. However, plasma MDA concentration was statistically significantly higher (p = 0.043) in cats with early CKD (IRIS stages 1 and 2) than in cats with advanced CKD (IRIS stages 3 and 4). Additionally, DNA damage was statistically significantly higher in healthy cats (p ≤ 0.001) than in CKD cats. Plasma vitamin E concentrations increased statistically significantly in the vitamin E group compared to the placebo group four (p = 0.013) and eight (p = 0.017) weeks after the start of vitamin E supplementation. During the study and after 24 weeks of vitamin E supplementation, plasma MDA and PC concentrations and DNA damage remained similar to pre-supplementation levels in both the placebo and vitamin E groups. Conclusions Vitamin E supplementation as an addition to standard therapy does not prolong survival in feline CKD.

show abstract

Section: Introductionmentioning

confidence: 99%

Supplementation of vitamin E as an addition to a commercial renal diet does not prolong survival of cats with chronic kidney disease

Krofič Žel,

Tavčar Kalcher,

Vovk

et al. 2024

BMC Vet Res

View full text Add to dashboard Cite

show abstract

Sodium glucose transporter 2 inhibitors: Will these drugs benefit non‐diabetic veterinary patients with cardiac and kidney diseases?

Elliott,

Oyama

2024

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

Sodium glucose transporter type 2 (SGLT2) inhibitors have been introduced into human medicine where their beneficial effects go beyond the expected improvement in blood glucose control. These drugs appear to prevent progression of both cardiovascular and kidney diseases, not only in diabetic but also in non‐diabetic human patients. As these drugs have received conditional approval for use in diabetic cats and are being used in other veterinary species, the intriguing question as to whether they will have similar cardioprotective and nephroprotective effects in dogs and cats is being asked. The primary mechanism(s) by which SGLT2 inhibitors are cardio‐ and nephroprotective remain to be fully characterized. This paper reviews these suggested mechanisms in the context of the pathophysiology of progressive cardiovascular and kidney diseases in dogs and cats with the goal of predicting which categories of non‐diabetic veterinary patients these drugs might be of most benefit.

show abstract

Immunohistochemical analysis of renal oxidative damage in senior and geriatric cats with chronic kidney disease

Cited by 2 publications

References 21 publications

Supplementation of vitamin E as an addition to a commercial renal diet does not prolong survival of cats with chronic kidney disease

Supplementation of vitamin E as an addition to a commercial renal diet does not prolong survival of cats with chronic kidney disease

Sodium glucose transporter 2 inhibitors: Will these drugs benefit non‐diabetic veterinary patients with cardiac and kidney diseases?

Contact Info

Product

Resources

About